tradingkey.logo
tradingkey.logo
Search

European Commission Approves Pfizer’S Hympavzi For The Treatment Of Adults And Adolescents With Hemophilia A Or B With Inhibitors

ReutersMay 13, 2026 10:46 AM
facebooktwitterlinkedin
View all comments0

- Pfizer Inc PFE.N:

  • EUROPEAN COMMISSION APPROVES PFIZER’S HYMPAVZI FOR THE TREATMENT OF ADULTS AND ADOLESCENTS WITH HEMOPHILIA A OR B WITH INHIBITORS

  • PFIZER : EUROPEAN COMMISSION APPROVES HYMPAVZI EXPANSION FOR HEMOPHILIA A/B PATIENTS AGES 12+ WITH INHIBITORS

  • PFIZER - HYMPAVZI MARKETING AUTHORIZATION VALID IN ALL 27 EU STATES, ICELAND, LIECHTENSTEIN, AND NORWAY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI